newsroom
AI in Healthcare · Digital therapeutics face broken economics: high FDA/payer barriers with low IP defensibility
now playing · AI in Healthcare
Removing employers as healthcare purchasers would align system incentives with consumers
Almost all healthcare dysfunction stems from the consumer not being the customer. Employers create churn and misaligned incentives; shifting to consumer-directed purchasing (like AT&T phone…
Eliminating rebates is the single highest-impact lever to fix drug price transparency
Rebates (40-50% of list price) destroy price signals for consumers and providers. Removing them would restore genuine price competition between drugs. PBMs currently optimize for payer (emp…
AI is a magical co-pilot for clinicians and consumers, not a replacement for doctors
Current LLMs are exceptional at synthesizing patient history, preparing visits, and stringing together operational follow-ups (prior auths, referrals, prescriptions), but are far from repla…
Digital therapeutics face broken economics: high FDA/payer barriers with low IP defensibility
DTx require drug-level clinical trials and payer reimbursement but lack patent protection (easy to copy), creating a go-to-market trap. Most would be better served as direct-to-consumer cas…
Policy debate focuses on patent extensions instead of accelerating breakthrough drug creation
Society should worry far more about the next Hepatitis C cure (which dropped from $100k to $15k in 6 months) not being invented than about Humira's patent thicket. The learning curve for bi…